TuHURA BiosciencesSTU:PL3 +0.51%14 5-Year RORE % is 0.00 as of Mar. 2026. GuruFocus rates STU:PL3 with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,138 Biotechnology companies, TuHURA Biosciences ranks worse than 87873.37% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
TuHURA Biosciences does not have enough data to calculate 5-Year RORE %.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
TuHURA Biosciences 5-Year RORE % Related Terms
TuHURA Biosciences 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for TuHURA Biosciences's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PL3 vs ACOG, MENS, ENLV: 5-Year RORE % Comparison
For the Biotechnology subindustry, TuHURA Biosciences's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TuHURA Biosciences 5-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where TuHURA Biosciences's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
TuHURA Biosciences (STU:PL3) has a 5-Year RORE % of 0.00 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on TuHURA Biosciences and its competitors. According to the industry distribution chart, TuHURA Biosciences ranks #999999 out of 1138 companies in the Biotechnology industry.
Is TuHURA Biosciences' 5-Year RORE % too high?
TuHURA Biosciences' current 5-Year RORE % is 0.00. Based on the distribution chart, TuHURA Biosciences ranks #999999 out of 1138 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TuHURA Biosciences has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does TuHURA Biosciences' 5-Year RORE % compare to ACOG and MENS?
According to the Biotechnology industry distribution chart, TuHURA Biosciences ranks #999999 out of 1138 companies for 5-Year RORE %. This places TuHURA Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on TuHURA Biosciences and its competitors. TuHURA Biosciences's current 5-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TuHURA Biosciences stock overvalued right now?
TuHURA Biosciences (STU:PL3) has a current 5-Year RORE % of 0.00. The current 5-Year RORE % is 0.00. TuHURA Biosciences' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For TuHURA Biosciences (STU:PL3), the current 5-Year RORE % is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
14GF Score
Get the complete analysis for STU:PL3
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PL3 has been successfully added to your 
